Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 187 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Professor Eithne Costello: On the road to early detection November 12, 2021 What if we count all that still remains? June 11, 2021 Good News and Cautions about Pregnancy for Childhood Cancer Survivors March 4, 2022 Survivor Story: Erin June 4, 2021 Load more HOT NEWS Triple negative breast cancer drug given initial ‘no’ for NHS in... What Is Peripheral Neuropathy and How Can It Be Prevented or... FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’...
